I’ll tell you right upfront: I love Johnson & Johnson (JNJ). It was one of my first picks when I started building my dividend portfolio. In all honesty, I think this stock is a keeper for life.

The company has more brands than you can count and each of them is worth hundreds of millions of dollars (when they aren’t worth billions). About 1/6 of its revenue comes from repeating sales in consumer products while it finds strong growth among pharmaceutical products.

Johnson & Johnson is among the rare companies to be part of the Dividend King list (with 50+ years of dividend increases). This morning, it published its latest revenues with both revenues and earnings beat. Unfortunately, there is something wrong with this company. Let’s find out what’s not to like about JNJ.

READ FULL ARTICLE HERE